Award
National Cancer Institute 1R01CA300313-01A1
Advancing a novel synthetic lethal target by exploiting ribosomal stress in Ch9p21.3-deleted or MSI-H cancers
Recipient
Columbia University Health Sciences
Award Amount
$501,422.00
Ceiling
$501,422.00
Awarded
April 02, 2026
Identifier
1R01CA300313-01A1
The project aims to validate and understand a synthetic lethal interaction as a therapeutic target for MSI-H and 9p21.3-deleted cancers, potentially leading to novel targeted cancer therapies.
Description
This NIH grant opportunity focuses on validating and mechanistically understanding the synthetic lethal interaction involving Pelota (PELO) and HBS1L in cancers with chromosome 9p21.3 deletions or MSI-H status, aiming to develop targeted therapies for these lethal cancer subtypes.